Vasculitis & polymyalgia rheumatica
Impact of mepolizumab on the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire in eosinophilic granulomatosis with polyangiitis: data from a European multicentre study
Authors' conclusion
Mepolizumab was associated with a quick and remarkable improvement of health-related quality of life in patients with EGPA.
Study context
- Population
- Patients with active eosinophilic granulomatosis with polyangiitis (EGPA) initiating mepolizumab, international multicentre European cohort63 (90%) relapsing/refractory
- Participants
- 70 patients
- Outcome
- Change in AAV-PRO questionnaire and patient global assessment (PtGA) scores, assessed at baseline and after 7, 14, 30, 90 and 180 days
Methodological detailsinternational, multicentre, single-group
- International
- Multicentre
- Single-group
Main finding
As reported in the abstract
Improvement at 6 months, organ-specific symptoms (ratio)
0.53
Improvement at 6 months, physical function (ratio)
0.57
Improvement at 6 months, patient global assessment (PtGA) (ratio)
0.58
Observational data: associations, not effects.
Further findings
Predictors of AAV-PRO scores
- PtGA and higher disease activity positively correlated with AAV-PRO scores throughout the study
- Female patients reported greater burden in systemic symptoms, treatment side effects, social and emotional impact and concerns about the future
- Age, educational level, damage accrual, mepolizumab dose and ANCA status had no effect on AAV-PRO scores
Original publication
Impact of mepolizumab on the AAV-PRO questionnaire in eosinophilic granulomatosis with polyangiitis: data from a European multicentre study. Rheumatology (Oxford). Published 26 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →